Form 4: Baker Bros. Funds Boost Kymera Therapeutics Stake

Baker Bros. affiliated funds significantly increased their holdings in Kymera Therapeutics, Inc. by purchasing over 2 million shares at $86.00 each in an underwritten offering.

Summary

• Baker Bros. affiliated funds, specifically 667, L.P. and Baker Brothers Life Sciences, L.P., acquired a combined total of 2,005,813 shares of Kymera Therapeutics, Inc. common stock.
• The shares were purchased at a price of $86.00 per share in an underwritten offering that closed on December 11, 2025.
• The total value of this acquisition was approximately $172.5 million.
• Following the transaction, 667, L.P. indirectly beneficially owns 701,326 shares of common stock.
• Following the transaction, Baker Brothers Life Sciences, L.P. indirectly beneficially owns 7,955,916 shares of common stock.
• Reporting persons include Baker Bros. Advisors LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, Julian C. Baker, and Felix J. Baker.
• Felix J. Baker is a director of Kymera Therapeutics, Inc., and other reporting persons are deemed directors by deputization for Section 16 purposes.
• All reporting persons are also identified as 10% owners of Kymera Therapeutics, Inc.

Sentiment

Score: 8

Explanation: The significant purchase of common stock by major institutional investors and insiders, including a director, indicates strong confidence in the company's valuation and future prospects. This is generally viewed as a very positive signal by the market.

Positives

• Significant investment by major shareholders and insiders, including a director, indicates strong confidence in Kymera Therapeutics' future prospects and valuation.
• The purchase was made at a substantial price of $86.00 per share, suggesting a belief in the company's current and future value.
• The transaction was part of an underwritten offering, which typically implies a structured capital raise for the company, providing it with additional funding.

Negatives

• No direct negatives are reported in this Form 4 filing, as it primarily details a stock acquisition.

Risks

• No specific risks are detailed in this Form 4 filing, which is a report of beneficial ownership changes.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Significant insider purchases by major institutional investors like Baker Bros. Advisors in the biotech sector often signal strong conviction in a company's pipeline, clinical trial progress, or market potential. Such investments can be viewed positively by the market, suggesting that those with deep industry knowledge and access to company specifics see substantial upside.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• Baker Bros. affiliated funds (667, L.P. and Baker Brothers Life Sciences, L.P.) purchased shares from Kymera Therapeutics, Inc. in an underwritten offering.
• Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, is a director of Kymera Therapeutics, Inc.
• Other reporting persons are deemed directors by deputization, establishing a related party relationship for the transaction.

Stakeholder Impact

• Shareholders: The significant insider buying could instill greater confidence in existing shareholders and attract new investors, potentially leading to positive share price movement.
• Company: The underwritten offering likely provided capital to Kymera Therapeutics, Inc., supporting its operations and strategic initiatives.

Next Steps

• This filing does not specify any future actions, events, or milestones for Kymera Therapeutics, Inc.

Key Dates

Recommendation

The substantial investment by Baker Bros. Advisors, a highly respected institutional investor with deep expertise in the biotech sector, and its affiliated funds, including a director of Kymera Therapeutics, Inc., signals strong conviction in the company's long-term value and prospects. This significant insider buying, especially at a price of $86.00 per share, suggests that these informed parties believe the stock is undervalued or poised for significant growth. Such a vote of confidence from a major shareholder and insider is a compelling indicator for potential investors.

Keywords

Kymera Therapeutics, KYMR, Baker Bros. Advisors, insider buying, stock purchase, beneficial ownership, Form 4, biotech, pharmaceutical, investment, capital raise